Inhaled nanoparticles have a high deposition rate in the alveolar units of the deep lung. The alveolar epithelium is composed of type-I and type-II epithelial cells (ATI and ATII respectively) and is bathed in pulmonary surfactant. The effect of native human ATII cell secretions on nanoparticle toxicity is not known. We investigated the cellular uptake and toxicity of silver nanowires (AgNWs; 70 nm diameter, 1.5 µm length) with human ATI-like cells (TT1), in the absence or presence of Curosurf ® (a natural porcine pulmonary surfactant with a low amount of protein) or harvested primary human ATII cell secretions (HAS; containing both the complete lipid as well as the full protein complement of human pulmonary surfactant i.e. SP-A,
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INTRODUCTION
Inhalation is potentially a key route of human exposure to engineered nanomaterials, from the perspective of both intentional (diagnostic and therapeutic applications) and unintentional scenarios. Understanding nanomaterial interactions with lung cells of the alveolar region is crucial, where inhaled nanoparticle deposition rate is high. The alveolar unit, at the lung periphery, forms the active gas-blood interface and is composed of alveolar type-I and type-II epithelial cells (ATI and ATII respectively) and underlying microvascular endothelial cells. ATI cells are highly attenuated, squamous cells (~200nm thick and 40 -80 µm in diameter; facilitating efficient gas exchange across the alveolar wall), which cover over 95% of the alveolar surface. 1 The cuboidal ATII cell, accounting for <5% of the total alveolar surface area, synthesises, secretes and recycles pulmonary surfactant, a lipid-protein compound that lowers surface tension at the alveolar air-liquid interface, preventing the lungs from collapsing at exhalation. Pulmonary surfactant is largely composed of phospholipids (~90% by mass) and proteins (~10% by mass) 2 Phosphatidylcholine predominates the phospholipid content in surfactant (~70% of total phospholipid weight), ~50% of which is saturated dipalmitoylphosphatidylcholine (DPPC), primarily responsible for surfactant's surface tension lowering capabilities. 3 Four functional apoproteins (surfactant protein A, B, C and D; SP-A, SP-B, SP-C and SP-D respectively) contribute to the structure and stability of pulmonary surfactant; the collectins SP-A and SP-D are also important effectors of immune recognition, opsonising foreign matter for enhanced alveolar macrophage phagocytosis. 4 Nanomaterials that deposit in the alveolar region following inhalation will interact firstly with pulmonary surfactant and other lung secretions before either they interact with alveolar macrophages or the alveolar epithelial cells. It is therefore critical to understand the effects of human pulmonary surfactant when evaluating the inhalation toxicity of nanoparticles. Both DPPC and Curosurf ® (a natural porcine pulmonary surfactant, purified to remove protein content) have been used to model the effect of pulmonary surfactant's lipid components on nanoparticle toxicity, [5] [6] [7] while SP-A and SP-D (generally isolated from rodent, porcine or human bronchoalveolar fluid) have been used to model the effect of pulmonary surfactant's immuno-protein component. [8] [9] [10] However, the effect of native human ATII epithelial cell secretions (which contain complete pulmonary surfactant lipids and proteins) on nanoparticle toxicity is not known.
According to the Project on Emerging Nanotechnologies (http://www.nanotechproject.org), nano-silver currently represents the greatest proportion of commercialised nanomaterials globally, with numerous biomedical existing applications and others in development. 11 In the present study, we investigated the toxicity and cellular uptake of silver nanowires (AgNWs; 70 nm diameter, 1.5 µm length) with human alveolar epithelial type I-like cells (TT1) cells following up to 24 hours of continuous exposure, in the absence/presence of Curosurf ® or harvested primary human ATII cell secretions (HAS). We also investigated the toxicity and cellular uptake of AgNWs with primary human ATII cells under the same exposure conditions as the TT1 cells. We hypothesised that both Curosurf ® and HAS would confer protection for TT1 cells, limiting the toxicity of AgNWs.
RESULTS AND DISCUSSION

Graphical summary
A graphical summary of AgNW interactions with TT1 cells, in the absence and presence of Curosurf or HAS, is depicted in Figure 1 
AgNW material physicochemical characteristics
The AgNWs used in this study were synthesised in-house and thoroughly characterised as previously reported by us. 12 A summary of the physicochemical characteristics of these AgNWs is shown in Table 1 .
HAS proteins binding to AgNWs
Only 10% and 13% of the total protein available in HAS bound to 1 and 25 µg/ml AgNWs respectively, following 1 hour incubation (Figure 2 a) . Interestingly, SP-A was specifically found to bind to AgNWs as indicated by both an increase in the amount of SP-A in the AgNWcontaining pellet and a decrease in the amount of SP-A in the corresponding supernatant following centrifugation (the amount of SP-A in the pellet significantly increased 2.4-fold with the addition of 25 µg/ml AgNWs; P < 0.05; Figure 2 b ). SP-D was also found to bind specifically to AgNWs. Strikingly, in contrast to SP-A, the presence of SP-D in the pellet after centrifugation was entirely due to the addition of AgNWs to the HAS i.e. SP-D was not detected in the pellet of HAS alone. Following the addition of 25 µg/ml AgNWs, the amount of SP-D in the pellet had a densitometry arbitrary unit (DAU) value of 1.51 x 10 7 compared to zero for HAS alone; P < 0.01; Figure 2 b ). The trend for 1 µg/ml AgNW was similar but less marked. This likely reflects the high solubility of SP-D, which does not bind to surfactant lipids and remains in the supernatant; 13 on incubation with AgNWs, SP-D binds to the AgNWs and hence can be located in the AgNW-containing pellet. Scanning transmission electron microscopy with energy dispersive X-ray spectroscopy (STEM-EDX) showed that incubation with HAS does not modify the chemical composition of the AgNWs (e.g. cause sulfidation; Supplementary Figure 1 ). This lack of activity is in accordance with previous findings demonstrating that AgNWs are not sulfided by isolated sulphur-containing amino acids or proteins, such as cysteine or bovine serum albumin.
14
AgNW uptake by TT1 and ATII cells
We have previously shown that AgNW uptake by TT1 cells is rapid (~1 hour). 12 Thus in the present study we chose to quantify AgNW uptake at both 1 hour and 24 hours using inductively 
Cell viability, IL-8 release and reactive oxygen species generation
We previously showed that AgNWs did not cause cell death nor increased the generation of reactive oxygen species in TT1 cells following 1 hour exposure. 12 In the present study we were Vranic et al recently showed that Curosurf ® has the ability to significantly reduce silicon dioxide uptake by human lung mucoepidermoid carcinoma cells (NCI-H292) and a murine alveolar macrophage cell line 15 . In contrast, Gasser et al showed that Curosurf ® acted to significantly increase uptake of multi-walled carbon nanotubes by human monocyte derived macrophages. 16 In the present study, Curosurf ® had no effect on uptake or toxicity, thus the effects of Curosurf glutathione. 18 We measured total levels of glutathione in HAS and found that the antioxidant is present in the secretions, however it does not spin down with AgNWs following centrifugation and therefore can not contribute to the reduction in ROS that we found (Supplementary Figure   4) . Treating ATII cells with AgNWs, for 4 or 24 hours, did not modify ROS levels (Figure 7 b) .
However, at Day 1 post-exposure, ATII cell ROS levels were significantly increased by 1.9-fold at the highest concentration of AgNW (P < 0.05).
ATII intracellular surfactant protein levels
Because we found that ATII cells, at Day 1 post-exposure, displayed increased bioreactivity 
CONCLUSION
It has been demonstrated that the protein component of ATII cell secretions dramatically reduces the uptake and bioreactivity of AgNWs by TT1 cells. We suggest that the surfactant proteins SP-A and SP-D are likely to be involved in these mechanisms, however they need further investigation. While the evidence presented here suggests ATII secretions act to prevent ATI cell uptake and reduce the bioreactivity of AgNWs, the ATII cells themselves were found to be vulnerable to AgNW exposure, even in the absence of AgNW uptake. The first interaction of any nanoparticle that reaches the alveoli will be with the pulmonary surfactant, including the proteins suggested here to be largely responsible for the observed reduction in AgNW uptake and bioreactivity. This study provides unique findings that are important for understanding interactions at the bio-nano interface of the alveolar unit and the impact these could have on subsequent epithelial-endothelial activity and nanoparticle translocation across the gas-liquid interface.
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EXPERIMENTAL Ethics Statement
The human lung tissue used in this study was surplus tissue obtained following resection for lung carcinoma. Written informed consent was obtained for all samples and the study was carried out with the approval of the Royal Brompton and Harefield Ethical Committee (Ref: 08/H0708/73).
TT1 and ATII cell models
This laboratory has previously immortalised human ATI-like cells (derived from freshly isolated and cultured primary human ATII cells) using transduction with the catalytic subunit of telomerase (human telomerase reverse transcriptase; hTERT) and a temperature sensitive mutant of simian virus 40 large-tumour antigen. 23 These ATI-like (transformed type-I-like; TT1) cells, the first human ATI-like cell line to be produced, are negative for the ATII cell markers SP-C, alkaline phosphatase and thyroid transcription factor-1. Moreover, TT1s do not contain lamellar bodies. They display a thin, attenuated morphology containing vesicles, being caveolae positive.
TT1 cells were cultured to confluence in either 24-well culture plates (for uptake study) or 96-well culture plates (for all other assays) using DCCM-1 tissue culture medium with 10 % FCS new-born calf serum, 0.05% G418 and 10% PSG. An initial cell seeding of 1 x 10 5 /well (24 well culture plate) 0.1 x 10 5 /well (96 well culture plate) yielded a confluent monolayer after 48 hours.
Growth medium was replaced with serum-free DCCM-1 24 hours prior to AgNW exposure.
Cells were incubated in humidified 5% CO 2 /95% air at 37°C.
Primary human ATII cells were isolated from human lung of grossly normal appearance obtained following resection for lung carcinoma, as described by Witherden and Tetley. 24 Cells were isolated from a minimum of three subjects per experiment, with a total of fifteen subjects used in this study. Briefly, lung tissue sections were perfused by injection of 0.15 M sterile sodium chloride saline solution until the draining lavage ran clear and the cell count was < 1x10 
24,25
AgNWs and preparation of Curosurf ® or HAS pre-incubated AgNWs PVP-capped nanowires were synthesised and thoroughly characterised as previously described. 
ICP-OES and Transmission Electron Microscopy analysis of AgNW uptake
Quantification of Ag in culture medium and cells
To quantify the amount of AgNWs taken up by TT1 and ATII cells, TT1 cells were treated with AgNWs (alone or + Curosurf ® or HAS) and ATII cells were treated with AgNWs (alone); the total amount of AgNWs added to TT1 or ATII cells for the uptake study was 25 µg (i.e. 1 ml of a 25 µg/ml concentration of AgNWs, prepared in RPMI 1640 culture medium, was used). Both TT1 and ATII cells were exposed for 1 and 24 hours, after which the treatments were removed. (Thermo Scientific, UK) with a silver detection limit of 0.6 ppb, following acid digestion.
Digestion procedures using only nitric acid (HNO 3 ) have been shown to produce inaccurate results for Ag analyses, whereas digestions based on mixtures of nitric and hydrochloric (HCl) acids lead to high Ag recovery rates 26 . Therefore, the cell pellets and 400 µL aliquots of the extracellular medium samples were digested with 5 mL of a 1:3 mixture of HNO 3 (69%) and HCl (37%) overnight. The samples were diluted 10 times in ultrapure water (Milli-Q), yielding clear digest solutions, and analysed by ICP-OES.
Transmission Electron Microscopy
Following the same treatment as described in the Quantification of Ag in culture media and cells, 
Measurement of inflammatory mediator release
TT1 or ATII cells were seeded on 96-well plates as described above. Following 4 and 24 hours treatment with AgNWs (alone or + Curosurf ® or HAS) and at the recovery time point, TT1 or ATII cell mediator-conditioned medium from was assayed for concentrations of the inflammatory chemokine, human IL-8, using sandwich enzyme-linked immunosorbent assays (ELISA). The assays were performed using DuoSet ® antibody kits and according to the manufacturer's directions (R&D systems, USA).
Generation of reactive oxygen species
TT1 or ATII cells were seeded on 96-well plates (black, with a clear bottom) as described above. 
Measurement of ATII intercellular SP-A/SP-D protein levels
After a post-exposure recovery period, ATII cells were lysed using Cell Lytic M (with protease inhibitor cocktail), incubated on ice for 30min and then centrifuged at 3000g for 20min at 4°C.
Protein concentrations from ATII extracts were determined using Bradford Reagent. Equal volume of samples (mixed with 4X NuPAGE LDS sample loading buffer and 10X NuPAGE sample reducing agent, then boiled at 100ºC) were loaded into NuPage 4-12% gels and electrophoretically separated using sodium dodecylsulphate-polyacrylamide gel electrophoresis (SDS-PAGE). Following gel electrophoresis, gels were rinsed in distilled water then transferred to the nitrocellulose membrane using the i-Blot™ Dry Blotting System (Invitrogen, UK). SP-A and SP-D protein on this membrane was then detected using the anti-human SP-A antibody, ab51891, and the anti-human SP-D antibody, ab97849 (both from Abcam, Cambridge, UK). SP-A and SP-D protein bands were imaged using Ultraviolet Transilluminator GelDoc-It and densitometric quantification was performed using Visionworks.
Statistical analyses
Data from viability, inflammatory mediator release, ROS generation and ATII intracellular levels of SP-A and SP-D experiments is presented as the mean ± standard error (where three independent experiments were performed using three separate TT1 passage generations and where four independent experiments were performed using five separate donor tissues for ATII studies). Significant differences in AgNW (dose or +/-Curosurf ® ) treatment on cell viability, inflammatory mediator release, ROS generation and ATII intracellular levels of SP-A and SP-D were determined using a parametric one-way analysis of variance with Bonferroni comparisons (for TT1 cell line experiments) and using a non-parametric Kruskal-Wallis test followed by Figure 1iii) . 
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